Gasotransmitters: Potential Therapeutic Molecules of Fibrotic Diseases

Figure 3

The interference mechanisms of CO in fibrotic diseases. Low-dose exogenous and endogenous CO can interfere with the TGF-β and NF-κB signaling pathway via reducing the expression of fibrosis and inflammatory-related genes. In addition, CO can also inhibit the TGF-β signaling by the stimulation of autophagy.